The upward revision in revenue guidance considers continued global development of Soliris for PNH, and the potential for an earlier than previously expected US launch of Soliris for aHUS. The earlier release could take place if the US regulatory submission is approved for concern review by the FDA and if a positive decision is definitely then received, making a start possible in the 4th quarter of 2011 late. Further, the upward revision considers the potential for disruptions in treatment for specific patients in Japan linked to the recent natural disasters for the reason that country.. Alexion submits Soliris marketing applications to FDA, EMA for aHUS treatment Alexion Pharmaceuticals, Inc. announced today that the company has submitted marketing applications to the U.S.There's not just a single activity level variable in these measurements, stated Dr. Brophy. This will depend on the populace, the injury you're studying, etc. We're making improvement, and the progress varies based on what you're looking at. .. AHF proposes innovative alternative to resolve AIDS drug crisis in Florida As the State of Florida grapples with a budget shortfall that is crippling its AIDS Drug Assistance Plan and forcing the state to place a lot more than 1,300 low-income Floridians on waiting lists to access lifesaving AIDS medications, AIDS Healthcare Foundation has proposed an innovative solution to state health officials and seven leading AIDS drug companies that would create a public/personal partnership to solve the drug crisis and get vulnerable Florida AIDS patients on to lifesaving antiretroviral treatment.